<DOC>
	<DOCNO>NCT00664586</DOCNO>
	<brief_summary>This Phase I continuous infusion study design explore constant concentration time add effectiveness terameprocol without increase toxicity . It also explore weekly dosing option . Tumor response assessment perform follow every two ( 2 ) cycle therapy . All subject undergo follow-up visit 30 day follow last dose terameprocol . Circulating tumor cell ( CTC ) quantify pre dose day 15 first dose cycle . Needle biopsy specimens take prior therapy one week first dose , possible , assess tumor marker ( cdc-2 survivin ) . Tumor marker , example prostate specific antigen ( PSA ) also measure day 15 cycle ( elevate study entry ) . Pharmacokinetic parameter derive analysis blood sample collect first 24 hour infusion .</brief_summary>
	<brief_title>A Phase 1 Continuous Intravenous Infusion Study Terameprocol ( EM-1421 ) Subjects With Refractory Solid Tumors</brief_title>
	<detailed_description>Subjects meet inclusion exclusion criterion enrol receive terameprocol weekly 24 hour intravenous infusion , three week four . Serial measurement safety perform prior dosing . Subjects screen within 28 day Cycle 1 . Hematologic , serum chemistry , tumor marker , pregnancy test perform . Circulating tumor cell assay perform . Needle biopsy specimens take prior therapy one week first dose , possible , assess tumor marker ( cdc-2 survivin ) . Subjects meet inclusion exclusion criterion enrol group 3-6 subject receive terameprocol weekly 24 hour intravenous infusion . The terameprocol dose level study include 100mg/hr , increase 25 mg/ hr increment next cohort assume DLT reach . Serial measurement safety perform visit . The MTD assess first Cycle treatment dose level . The use myeloid colony-stimulating factor allow prophylactically cycle 1 may use clinically indicated allow subsequent cycle prevent development neutropenia subject establish history adverse event earlier cycle . Each subject cohort treat dose schedule weekly infusion . Dose escalation subject may allow safe evaluation high dosage , two cycle complete stable disease well . Terameprocol ( EM-1421 ) administer intravenous infusion 24 hour , weekly . Dose commence first cohort 100 mg per hour ( 2400 mg 24 hour period ) escalation 5 cohort 3 6 patient increment 25 mg per hour maximum 200 mg/hr ( 4800 mg/24 hour period ) MTD define . When MTD declare , 11 additional subject enrol MTD dose level ( total 14 subject treat dosage cohort ) . Cohort A. receive weekly Terameprocol 100 mg per hour ( 2400 mg 24 hour period ) Cohort B. receive weekly Terameprocol 125 mg per hour ( 3000 mg 24 hour period ) Cohort C. receive weekly Terameprocol 150 mg per hour ( 3600 mg 24 hour period ) Cohort D. receive weekly Terameprocol 175 mg per hour ( 4200 mg 24 hour period ) Cohort E. receive weekly Terameprocol 200 mg per hour ( 4800 mg 24 hour period )</detailed_description>
	<mesh_term>Masoprocol</mesh_term>
	<criteria>1 . Male female subject great equal 18 year age . 2 . Subjects provide write informed consent participate study . 3 . Subjects document evidence cancer clinically measurable evaluable disease . Cancer recurrent primary treatment surgery , radiation therapy and/or chemotherapy may include subject standard curative therapy exists . 4 . Measurable tumor imaging ( CT per RECIST criterion ) . unless establish tumor marker exist use assessment response absence measurable disease ( i.e. , PSA prostate cancer CA 125 ovarian cancer ) . 5 . No recent myocardial infarction ( within 3 month ) serious intercurrent cardiovascular disease ( event require evaluation cardiologist , definitive cardiac disease diagnose ) Subjects history severe cardiac disease recent consultation cardiologist document new finding . 6 . No overt cardiac metastasis . 7 . Negative pregnancy test woman childbearing potential within one week start therapy . 8 . ECOG Performance Status 0 , 1 , 2 . 9 . Absolute neutrophil great equal 1500 cells/uL , hemoglobin great equal 9 gm/dl , platelet great equal 100,000/uL , ALT/AST le equal 3 x ULN ( upper limit normal range ) unless involve tumor le 5 x ULN , bilirubin le equal 1.5 x ULN , creatinine le equal 1.5 x ULN , normal creatinine clearance great 60 mL/min normal serum bicarbonate . Normal define local laboratory specification . Subjects meet follow criterion consider eligible participation study : 1 . Women pregnant breastfeeding ( woman childbearing potential must negative serum pregnancy test within one week enter study ) . 2 . Women childbearing potential unwilling use two medically acceptable form contraception course study ( surgical sterilization , approve hormonal contraceptive , barrier method spermicide ) . 3 . Subjects unable comply study requirement . 4 . Subjects know sensitivity study medication component . 5 . Subjects exhibit follow : mark baseline prolongation QT/QTc interval ( repeat demonstration calculate QTc interval &gt; 450 ) , history additional risk factor TdP ( e.g . heart failure , hypokalemia , family history long QT Syndrome ) , subject unable unwilling refrain use medication know prolong QT/QTc ratio course study . Subjects recently take medication must five halflives medication participation . 6 . Subjects exist port compatible terameprocol formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Terameprocol ( EM-1421 )</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Infusion</keyword>
	<keyword>Refractory Solid Tumors</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>Tumor Response</keyword>
	<keyword>Tumor Markers</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>